On November 12, 2026 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, reported that it will host a key opinion leader (KOL) webinar on Tuesday, December 1, 2026, at 8:00 a.m. ET to discuss the evolving treatment landscape in metastatic castration-resistant prostate cancer (mCRPC) and the potential of ATNM-400, its investigational, first-in-class, HER3-targeted Actinium-225 antibody radioconjugate.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature Michael J. Morris, MD, Prostate Cancer Section Head at Memorial Sloan Kettering Cancer Center, who will join members of Actinium’s management team for the discussion. Participants can register for the webinar here.

The webinar will explore the applicability of a HER3-targeted radiotherapeutic across the broad mCRPC population, including those patients with low or negative PSMA expression and those who do not respond to or progress following PSMA-directed treatments. The discussion will also examine the role of HER3 in tumor progression and treatment resistance, the rationale for targeting HER3 with alpha radiotherapy, and the potential role of non-PSMA approaches in the evolving prostate cancer treatment paradigm.

Actinium management will review previously reported findings from ATNM-400’s ongoing first-in-human Phase 1 study, HERACT-PRO-1, including initial data presented at the 2026 European Association of Nuclear Medicine (EANM) Congress. HER3-targeted PET imaging demonstrated tumor uptake and retention through Day 7, with no dose-limiting toxicities, xerostomia or Grade 3/4 hematologic adverse events observed in the initial three-patient cohort at the 1.0 µCi/kg dose level. Dose escalation has advanced to the second dose level of 1.5 µCi/kg and is ongoing. Additionally, further detail on the RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) imaging study to validate ATNM-400’s pan-tumor potential will be discussed. Management will also highlight preclinical findings demonstrating ATNM-400’s activity across prostate cancer models with varying PSMA expression and will review clinical plans for ATNM-400 in prostate cancer and additional solid tumors, including lung, breast, colorectal and ovarian cancers.

A live question-and-answer session will follow the presentations.

Webinar Details

Date: Tuesday, December 1, 2026
Time: 8:00 a.m. Eastern Time
Registration: Here

The live webcast will be accessible through the registration link above. A replay will be available following the event through the Events and Presentations section of Actinium’s website at www.actiniumpharma.com.

About Michael J. Morris, MD

Michael J. Morris, MD, is Prostate Cancer Section Head at Memorial Sloan Kettering Cancer Center and a leading investigator in the development of targeted radiopharmaceuticals for prostate cancer. He helped lead the pivotal Phase 3 VISION trial of lutetium-177–PSMA-617, which supported the initial FDA approval of Pluvicto, and is the lead author of the Phase 3 PSMAfore publication. His expertise spans clinical trial development, molecular imaging and the integration of radiopharmaceuticals into prostate cancer care.

About ATNM-400

ATNM-400 is an investigational antibody radioconjugate that pairs the HER3-targeting monoclonal antibody barecetamab with the alpha-emitting isotope Actinium-225. Its antibody-based design combines antigen-specific targeting with the potential for sustained tumor localization, supporting prolonged delivery of high-energy alpha radiation. Tumor uptake and retention observed through Day 7 with the ⁸⁹Zr-labeled imaging counterpart support this development rationale alongside the approximately 10-day half-life of ²²⁵Ac. The theranostic approach enables noninvasive visualization of antibody distribution to inform therapeutic development. The program is being evaluated in a first-in-human dose-escalation Phase 1 study of ATNM-400 in mCRPC, HERACT-PRO-1, which utlizes Zirconium-89-labeled barecetamab PET imaging to assess tumor targeting, biodistribution and dosimetry. Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.

ATNM-400 is differentiated from PSMA-targeted radiotherapies by its focus on HER3, an antigen implicated in tumor survival and treatment resistance. PSMA-directed approaches include Novartis’ Pluvicto and a broad pipeline of investigational therapies, including Telix Pharmaceuticals’ TLX591-Tx, Clarity Pharmaceuticals’ ⁶⁷Cu-SAR-bisPSMA, Convergent Therapeutics’ CONV01-α, AstraZeneca’s AZD2265 (formerly FPI-2265), Curium’s lutetium-177 zadavotide guraxetan (¹⁷⁷Lu-PSMA-I&T), ARTBIO’s AB001 and AdvanCell’s ADVC001. These programs span small-molecule and antibody-based therapies using beta- or alpha-emitting isotopes. ATNM-400 combines HER3 targeting with an Actinium-225 antibody radioconjugate, offering a distinct biological approach with the potential to expand radiotherapy across the broad mCRPC population, including patients with PSMA-low or PSMA-negative disease and those who do not respond to or progress following PSMA-directed treatment. Its HER3-directed mechanism also supports investigation beyond prostate cancer in other HER3-expressing solid tumors.

About HER3

HER3, also known as ERBB3, belongs to the epidermal growth factor receptor family and participates in signaling pathways that promote tumor growth, survival and treatment resistance. HER3-directed antibody-drug conjugates (ADCs) in clinical development include BioNTech and MediLink’s BNT326/YL202; Bristol Myers Squibb and SystImmune’s EGFR × HER3 bispecific ADC, izalontamab brengitecan (iza-bren); and Daiichi Sankyo and Merck’s patritumab deruxtecan (HER3-DXd). These programs highlight clinical development interest in HER3 as an oncology target. ATNM-400 takes a different payload approach, delivering alpha radiation rather than a conventional cytotoxic drug. Preclinical activity in prostate, non-small cell lung, breast, colorectal and ovarian cancer models supports investigating ATNM-400 as a potential pan-cancer radiotherapy, both as monotherapy and in rational combinations.

(Press release, Actinium Pharmaceuticals, NOV 12, 2026, View Source [SID1234674701])